The range of molecular formats being explored in drug discovery and development has expanded far beyond standard monoclonal antibodies to bispecific antibodies, asymmetric antibodies and many other intricate recombinant proteins. This shift has resulted in the development of more precise therapies for various diseases that are safe and effective but has also introduced new challenges in the drug development and manufacturing process. Lonza’s GS System® has been developed and optimized over the last 35 years to help pharmaceutical and biotechnology companies keep up with the rapidly changing demands of the drug development industry from the growing prevalence of diverse molecular formats to the increasing pressures on timelines to get molecules to market.
In this GEN webinar, our speaker Jin Lu, Ph.D., discusses latest additions to the GS® expression toolbox and shares strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During the webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems. Key learning objectives for the webinar are:
- How the GS System® can keep pace with industry challenges associated with the expression of diverse biotherapeutic proteins with its evolving suite of optimized tools and technologies
- How GS Discovery® can drive ~30-fold increases in transient titres, and uses the same CHO cell line, vectors and technologies as stable processes to streamline the transition from discovery through to stable production and commercial supply
- How the recently launched GS Effex® cell line enables developers of cancer immunotherapies to produce mAbs with increased potency, and the bYlok® bispecific format enables bispecific developers to overcome challenges associated with chain mispairing.